MSD India's out-of-the-box Hep C financing: how, why & what next?
This article was originally published in Scrip
Executive Summary
When Biotechnology Industry Organization (BIO) president and CEO Jim Greenwood suggested that consumers paying for their expensive cancer or hepatitis C virus (HCV) treatments through direct financing deals with manufacturers may be a possible solution to dealing with the high prices of some prescription medications (scripintelligence.com 9 June 2014), he probably didn't realize that smart Merck & Co executives in India were already experimenting with a pilot along those lines.